Tokyo, July 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062258) titled 'Initial Real-World Experience of Enfortumab Vedotin Combined with Pembrolizumab for Unresectable Urothelial Carcinoma in Shinshu University-Affiliated Centers' on July 16.
Study Type:
Observational
Primary Sponsor:
Institute - Shinshu University
Condition:
Condition - metastatic/unresectable Urothelial carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Following the EV-302 trial, which demonstrated the efficacy of combination therapy with Enfortumab Vedotin and Pembrolizumab (EV+P), this regimen has been established as the current standard first-line tr...